A phase II clinical study of a new anti-IL-23p19 monoclonal antibody was conducted in the given context, with 75% of individuals suffering from moderate-to-severe plaque psoriasis achieving a PASI 75 by week 16, demonstrating promising efficacy for IL-23 inhibition in psoriasis treatment. The gene discussed is IL23A; the disease is psoriasis vulgaris.